Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005819 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [18F]APN-1607 as a PET Biomarker
A Phase 1 study, sponsored by Invicro.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05005819 is a Phase 1 study that has completed, run by Invicro. The registered enrollment target is 12 participants.
The verdict
NCT05005819, a Phase 1 study, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The overall goal of this protocol is to evaluate \[18F\]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.
Interventions
- DRUG [18F] APN-1607
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-25 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05005819
The ClinicalTrials.gov registry entry for NCT05005819 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invicro, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F] APN-1607 is the first listed.
NCT05005819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05005819 about?
NCT05005819 is a clinical study titled "Evaluation of [18F]APN-1607 as a PET Biomarker". The overall goal of this protocol is to evaluate \[18F\]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.
What is the current status of trial NCT05005819?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-05-25. Estimated completion is 2024-01-09.
What interventions are being tested in trial NCT05005819?
The interventions under investigation include: [18F] APN-1607 (DRUG).
Who is sponsoring clinical trial NCT05005819?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.